NEW YORK (GenomeWeb News) – Hologic has entered into a definitive agreement to sell its LifeCodes business to Immucor for up to $95 million, the companies announced after the close of the market on Thursday.

LifeCodes was a part of Gen-Probe, which Hologic acquired when it bought the firm last summer. Gen-Probe had purchased LifeCodes as part of its acquisition of Tepnel Life Sciences in 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.